Clinical Trial Update: The Effect of 21-Days Intranasal Oxytocin on Patients With Post Traumatic Stress Disorder (PTSD) [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the effects of 21 days of intranasal oxytocin in patients with post-traumatic stress disorder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-traumatic Stress Disorder

Drugs mentioned

• intranasal oxytocin (oxytocin)

Snippet

Sponsor: Rambam Health Care Campus | Conditions: PTSD | Phase 4 | Status: UNKNOWN